非小细胞肺癌治疗方案的药物经济学评价综述

• 药品评价-循证医学研究 • 上一篇下一篇

非小细胞肺癌治疗方案的药物经济学评价综述

钱焊森,马爱霞

中国药科大学,中国药科大学国际医药商学院

收稿日期:2016-11-22 修回日期:2017-01-16 出版日期:2017-02-25 发布日期:2017-01-25
基金资助:
2015年中国药科大学“华海药业研究生创新基金”资金资助（基金编号：CX15S-014HH）

Review of Pharmacoeconomics Evaluation of Non-small Cell Lung Cancer

China Pharmaceutical University,

Received:2016-11-22 Revised:2017-01-16 Online:2017-02-25 Published:2017-01-25
Supported by:
2015 China Pharamaceutical University

摘要/Abstract

摘要： 目的：本研究旨在对国内外非小细胞肺癌（NSCLC）治疗方案的药物经济学评价进行分析，发现国内评价中存在的不足。方法：检索CNKI、万方、Pubmed、EMbase等数据库，筛选出文章20篇，分析模型、成本、产出等要素。结果：国内评价模型大多采用决策树模型，不能反映非小细胞肺癌治疗的长期效果，成本的测算也仅考虑直接医疗成本，研究中大多选择有效率等，未能综合考虑产出。结论：在进行非小细胞肺癌的药物经济学评价时，Markov或半Markov是较为合理的模型选择，成本测算时以全社会的角度更为合理，质量调整生命年（QALYs）也是更加全面的产出指标。

Abstract: Objective： To analyze Chinese and English literatures for pharmacoeconomics evaluations of non-small cell lung cancer（NSCLC）treatment patterns.Methods：We searched literatures in CNKI， Wanfang， Pubmed， and EMbase， and selected 20 literatures， analyzed their model， cost and outcome.Results：Decision models are widely used in Chinese researches， but they can hardly show treatment effectiveness in the long term.Most studies only take into account direct medical cost and response rate， which have several limitations.Conclusion：Markov or semi-Markov is suggested in such research， cost in the perspective of the whole society is more advisable， and QALYs can better describe patients’outcome.

钱焊森,马爱霞. 非小细胞肺癌治疗方案的药物经济学评价综述[J]. .

参考文献

[1] 刘国恩.中国药物经济学评价指南及导读(2015版)[M]. 北京: 科技出版社, 2015.
[2] 中华人民共和国国家统计局. 中国卫生与计划生育统计年鉴[M]. 北京: 中国协和医科大学出版社, 2015.
[3] 美国疾控预防中心：https://nccd.cdc.gov/uscs/toptencancers.aspx.
[4] Villaruz LC, Socinski MA.Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes[J].Eur J Cancer, 2016, 56: 162-171.
[5] 张春香, 张红梅, 师锦宁,等.厄洛替尼对比培美曲塞治疗晚期非小细胞肺癌的药物经济学分析[J].中国新药杂志, 2015(14): 1616-1623.
[6] 夏佳. 非小细胞肺癌全切术后治疗方案的临床决策研究. : 四川大学; 2006.
[7] 欧阳丽辉, 彭六保, 袁铁流.培美曲塞在非小细胞肺癌患者中维持治疗的成本效果分析[J].中国医院药学杂志, 2015(17): 1575-1580.
[8] Zhang C, Zhang H, Shi J,etc..Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China[J]., 2016, 11(3): e151846.
[9] 欧阳丽英.评价两种一线化疗方案在表皮生长因子受体突变的晚期非小细胞肺癌患者的成本-效果[J].中国新药与临床杂志, 2016(02): 138-144.
[10] 张媚媚, 庞廷媛, 高文慧,等.晚期非小细胞肺癌4种化疗方案的药物经济学评价[J].中国医院药学杂志, 2016(22): 1-4.
[11] 方洁, 沈潜, 杨婉花.非小细胞肺癌常用化疗方案的药物经济学分析[J].中国新药与临床杂志, 2010(12): 942-945.
[12] 费小非, 汤致强.晚期非小细胞肺癌四种化疗方案的成本-效果分析[J].中国药事, 2007(03): 204-207.
[13] Lim EA, Lee H, Bae E,etc..Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea[J]., 2016, 11(8): e160155.
[14] Zeng X, Li J, Peng L,etc..Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis[J]., 2014, 9(2): e88881.
[15] Narita Y, Matsushima Y, Shiroiwa T,etc..Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer[J]., 2015, 90(1): 71-77.
[16] Chouaid C, Crequit P, Borget I,etc..Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review[J]., 2015, 7: 9-15.
[17] Brown T, Pilkington G, Bagust A,etc..Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation[J]., 2015, 17(31): 281-282.
[18] Patel K, Montouchet C, Cheynel J,etc..A Cost-Effectiveness Analysis of EGFR-TK Mutation Status-Guided 1st- and 2nd-Line Treatment of Stage III/IV Non-Small Cell Lung Cancer in the UK[J]., 2014, 17(7): A635-A636.
[19] Sanders GD, Neumann PJ, Basu A,etc..Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.[J].JAMA, 2016, 316(10): 1093-1103.
[20] 刘敏, 温成泉, 高蕾,等.非小细胞肺癌几种化疗方案的药物流行病学分析[J].中国医刊, 2014(09): 83-85.
[21] 周蕾, 刘嘉湘, 李和根,等.两种方案治疗晚期非小细胞肺癌的临床疗效及成本-效益比较研究[J].上海中医药杂志, 2012(05): 21-23.
[22] 徐艳.晚期非小细胞肺癌四种化学治疗方案的成本-效果分析[J].实用医技杂志, 2013(02): 194-195.
[23] 李玉平, 张晓庆, 胡苹,等.胸腺五肽联合TP方案治疗晚期非小细胞肺癌的成本-效果分析[J].中国药房, 2013(04): 329-332.